Fresh analysis reveals that patients who come off popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise programs.
Published data in a major medical journal demonstrates that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such drugs need to be cognizant of the risk of fast rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting weight within about a year and a half.
Analyzing Approaches
The research, which reviewed 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
The team point out that individuals who lose weight through lifestyle changes alone generally have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors suggest the way of the jabs is key to understanding the accelerated rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone concentrations far above than normal might result in the body to produce less of its own natural hormone, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means hunger is unsuppressed, making binge eating far more likely."
An Ongoing Condition?
Medical guidelines advise the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of weight regain, the therapy might need to be life-long.
This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the persistent character of obesity," similar to managing diseases like hypertension.
Patient Experiences
Users who have stopped the medication describe a intense return of appetite.
"It was like something flipping and you become starving," recalled an individual.
This difficulty is compounded if individuals have not established permanent dietary or behavioural changes during therapy.
Widespread Use
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Finally, clinicians stress that while the jabs are potent tools for shedding pounds, they are not a magic fix and maintained weight loss likely depends on combined behavioural management.
